Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
NCT03424473
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Interventions
DRUG:
Tucatinib
Sponsor
Seagen Inc.